Login

I cannot remember my username

Technology Profits Confidential

The world of tech and biotechnology will provide endless opportunity for growth and wealth for investors who know where to look.

Technology Profits Confidential is your one-stop shop for the companies of tomorrow's technology... and how you can profit from them.

Flash Sell: Sail Away From Our December Trade With a 210% Profit!

By Ray BlancoPosted July 17, 2015

This company has been rising in part due to good news from its research and development efforts. Today, I want you to take a big profit from this company that just turned into a triple!

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

LoginGet Access

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits and Technology Profits Daily. Ray has been with Seven Figure Publishing for nine years. In 2018, his closed positions in Technology Profits Confidential averaged over 100% gains.

View More By Ray Blanco

Related Posts

A Dark Day in the Annals of Drug Regulation

By Ray BlancoPosted October 31, 2014

Everything was lining up for one of our biotech companies to file for early approval of its revolutionary drug Duchenne muscular dystrophy (DMD). Earlier in the year, the FDA provided the company with guidance about the data it needed for the company to file for approval, so that the drug could get to market as soon as possible…

New Data From Amicus Therapeutics

By Ray BlancoPosted February 15, 2013

I have some news today, headed by recent data from Amicus Therapeutics. The company has seen its share price drop after a placebo group in a study for its lead program showed an unusual amount of improvement. That, in turn, meant that the active arm in the trial didn't show a statistical benefit.

Ebola Reaches the U.S.

By Ray BlancoPosted October 3, 2014

It appears Ebola has reared its ugly head on this side of the Atlantic. With the burgeoning number of infections overseas, it was only a matter of time. A Liberian citizen infected with the virus by the name of Thomas Eric Duncan boarded a flight bound out of Liberia's capital and, by a circuitous route through several countries, ended up in Texas. As many as 100 Americans are suspected of possible exposure and are being watched. His family here in the States is under quarantine and observation. His home country is considering charging him with a crime for doing this, but considering the deadly nature of the disease and the severe strain on a Liberian health care system that is turning sick people away from hospitals because it can't handle any more cases, his decision could be considered rational, if saving his your own life is the ultimate consideration. In a U.S. hospital, with the best supporting care and possible access to an experimental drug, Duncan at least has a fighting chance to live.

Trade War Can’t Stop Tech Growth

By Ray BlancoPosted July 13, 2018

They tell us that there’s a trade war going on, but there’s no way to tell if you look at the bones of the tech market. In fact, the semiconductor market has been growing like crazy…